From the authors

European Respiratory Journal

Volumn 48, Issue 5, 2016, Pages 1527-1529

  Tadolini, Marina ^a   Lingtsang, Rangjung Dolma ^b   Tiberi, Simon ^c   Enwerem, Martin ^d   D'Ambrosio, Lia ^e,f   Sadutshang, Tsetan Dorji ^b   Centis, Rosella ^e   Migliori, Giovanni Battista ^e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Delek Hospital   (India)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d Amity Health Consortium   (South Africa)

^e IRCCS   (Italy)

^f Public Health Consulting Group SAGL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; DELAMANID; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

CARDIOTOXICITY; DRUG POTENTIATION; DRUG SAFETY; ELECTROCARDIOGRAPHY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HYPOKALEMIA; LETTER; PRIORITY JOURNAL; QT PROLONGATION; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; MULTIDRUG RESISTANT TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CLOFAZIMINE; DIARYLQUINOLINES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; NITROIMIDAZOLES; OXAZOLES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84994249018     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01552-2016     Document Type: Letter

References (10)

1. Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016; 48: 935-938.
2. D'Ambrosio L, Tadolini M, Centis R, et al. Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. Int J Infect Dis 2015; 32: 156-160.
3. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
4. Choudhri SH, Harris L, Butany JW, et al. Clofazimine induced cardiotoxicity -a case report. Lepr Rev 1995; 66: 63-68.
5. de Carsalade GY, Wallach D, Spindler E, et al. Daily multidrug therapy for leprosy; results of a fourteen-year experience. Int J Lepr Other Mycobact Dis. 1997; 65: 37-44.
6. Jarand J, Davis JP, Cowie RL, et al. Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest 2016; 149: 1285-1293.
7. Hwang TJ, Dotsenko S, Jafarov A, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open 2014; 4: e004143.
8. Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 3114-3120.
9. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis (2016 update). Document WHO/HTM/TB 2016.04. Geneva, World Health Organization, 2016.
10. Sotgiu G, Tiberi S, D'Ambrosio L, et al. Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503-1507.